Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/12/2025 ,inter alia, to consider and approve 1. To consider and approve the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astonea Labs has called a Board meeting on December 3, 2025 to consider multiple items, including approval of the AGM notice and Directors' Report for FY 2024-25. The board will also accept the resignation of Director Mr. Pardeep Singh (DIN: 10345015) and appoint a new Company Secretary & Compliance Officer. Notably, the board will evaluate a proposed acquisition of an equity stake in Damaira Pharmaceuticals Private Limited and consider setting up multiple foreign/wholly owned subsidiaries. Other items include the voluntary transition from Indian Accounting Standards (AS) to Ind AS, corporate office relocation, and adoption of several governance policies including RPT Policy and Material Subsidiary Policy.
The acquisition of Damaira Pharma stake and planned foreign subsidiaries signal business expansion that could be positive for long-term growth, while the director resignation may raise mild governance concerns. Investors should watch for detailed disclosures after the meeting, especially deal size and funding plans for the international expansion.